Esperion rockets as FDA backs cholesterol drug for regulatory filing

20 March 2017

US lipid management firm Esperion Therapeutics (Nasdaq: ESPR) leapt as much as 52% in morning trading today, after getting positive regulatory feedback on its cholesterol lowerer. The stock was still up 51.1% at $35.80 by late morning

The US Food and Drug Administration recently confirmed that Esperion’s low density lipoprotein cholesterol (LDL-C)-lowering program is adequate to support approval of an LDL-C lowering indication for bempedoic acid, the company revealed this morning.

Esperion plans to submit a New Drug Application by first-half 2019 for an LDL-C lowering indication based on the successful completion of the global pivotal Phase III program. The proposed product label would include specific language for use of bempedoic acid as an adjunct to maximally tolerated statin therapy in patients with hypercholesterolemia, specifically those at high cardiovascular disease (CVD) risk with atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH) who require additional LDL-C lowering.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK